Adding abiraterone to standard treatment improves prostate cancer survival by 40 per cent

Adding abiraterone to hormone therapy at the start of treatment for prostate cancer improves survival by 37 per cent, according to the results of one of the largest ever clinical trials for prostate cancer presented at the 2017 ASCO Annual Meeting in Chicago and published in the New England Journal of Medicine on Saturday. The results from the Cancer Research UK-funded STAMPEDE trial could change the standard of care for men with prostate cancer, making abiraterone a first-line treatment alongside hormone therapy.  

See original article at: https://www.cancerresearchuk.org/about-us/cancer-news/press-release/2017-06-03-adding-abiraterone-to-standard-treatment-improves-prostate-cancer-survival-by-40-per-cent